Mazowiecki Szpital Onkologiczny Sp. z o.o.

The oncology clinic at Mazowiecki Szpital Onkologiczny Sp. z o.o. is evaluating innovative surgical and ablative techniques to improve outcomes for patients with bladder, lung and breast cancers. Current studies compare new device‑based therapies with standard surgery to reduce recurrence and enhance recovery.

• Evaluation of UGN‑102 for non‑muscle invasive bladder cancer
• Neoadjuvant pembrolizumab combined with surgery in triple‑negative breast cancer
• Minimally invasive resection strategies for early‑stage non‑small cell lung cancer

With 18 active trials and a team of 15 investigators, the department leverages its surgical expertise to test next‑generation treatments while maintaining patient safety.

Research at the center focuses on malignancies of the blood and lymphatic system, notably metastatic castration‑resistant prostate cancer (mCRPC). Trials aim to determine whether adding targeted agents to chemotherapy can prolong survival and delay disease progression.

• Capivasertib plus docetaxel versus placebo in mCRPC
• Combination immunotherapy approaches for lymph‑node involvement in advanced cancers
• Biomarker‑driven studies assessing treatment response in hematologic tumors

The site’s multidisciplinary team collaborates with national oncology networks, offering patients access to cutting‑edge therapeutic options in a hospital setting.

The oncology department conducts a broad portfolio of trials targeting solid tumors, including ER+/HER2‑negative breast cancer, EGFR‑mutated non‑small cell lung cancer, urothelial carcinoma, and advanced gastric adenocarcinoma. Studies primarily evaluate novel immunotherapies, targeted inhibitors, and combination regimens to improve disease‑free and overall survival.

• Pembrolizumab combined with chemotherapy in HR+/HER2‑negative breast cancer
• Osimertinib adjuvant therapy for EGFR‑mutated NSCLC after resection
• BT8009 plus pembrolizumab versus standard chemotherapy in metastatic urothelial cancer
• Pumitamig plus chemotherapy versus bevacizumab in metastatic colorectal cancer

Hosting 18 clinical investigations, the site integrates diagnostic imaging and molecular profiling to personalize treatment pathways for each patient.

In addition to medical interventions, the clinic addresses the psychosocial needs of cancer patients through studies on quality‑of‑life and mental‑health support. Trials assess the impact of counseling, stress‑reduction programs, and digital health tools on treatment adherence and overall wellbeing.

• Evaluation of mindfulness‑based stress reduction on chemotherapy tolerance
• Digital symptom‑tracking platform to improve patient‑reported outcomes
• Psychological counseling interventions for patients with advanced disease

By integrating behavioral research with oncologic care, the department promotes a holistic approach that benefits both patients and caregivers at the Wieliszew hospital.